StockNews.com Downgrades Agios Pharmaceuticals (NASDAQ:AGIO) to Sell

Agios Pharmaceuticals (NASDAQ:AGIO) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Friday.

Several other research analysts also recently commented on the stock. Scotiabank increased their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a report on Monday, December 9th. Royal Bank of Canada raised their price target on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $56.33.

Agios Pharmaceuticals Trading Down 0.2 %

Shares of NASDAQ AGIO opened at $33.22 on Friday. The firm has a market capitalization of $1.89 billion, a PE ratio of 2.92 and a beta of 0.88. Agios Pharmaceuticals has a 12 month low of $24.88 and a 12 month high of $62.58. The firm has a fifty day simple moving average of $35.19 and a two-hundred day simple moving average of $43.38.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 2,051.38% and a negative return on equity of 2.93%. On average, sell-side analysts predict that Agios Pharmaceuticals will post -0.46 earnings per share for the current year.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,804 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares of the company’s stock, valued at approximately $608,395.08. This represents a 12.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.93% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of AGIO. Venturi Wealth Management LLC acquired a new position in shares of Agios Pharmaceuticals in the fourth quarter valued at about $33,000. Wingate Wealth Advisors Inc. purchased a new stake in shares of Agios Pharmaceuticals during the 4th quarter worth about $53,000. Sterling Capital Management LLC grew its position in shares of Agios Pharmaceuticals by 818.0% during the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 1,587 shares during the period. KBC Group NV grew its stake in Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 611 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Agios Pharmaceuticals by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 363 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.